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Abstract
Background: Development of new and effective therapeutics for sexually transmitted herpes simplex virus-2 (HSV-
2) infection is important from public health perspective. With an aim to identify natural products from medicinal
plants, in the present study, the potential of Terminalia chebula Retz was investigated for its activity against HSV-2.
Methods: Fruits of Terminalia chebula Retz were used to prepare 50% ethanolic extract. In addition, chebulagic acid
and chebulinic acid both purified from T. chebula were also used. The extract as well as purified compounds were
first used to determine their in vitro cytotoxicity on Vero cells by MTT assay. T. chebula extract, chebulagic acid,
chebulinic acid along with acyclovir were subsequently assessed for direct anti-viral activity, and their ability to
inhibit attachment and penetration of HSV-2 to the Vero cells. In addition, their anti-HSV-2 activity was also
determined by in vitro post-infection plaque reduction assay.
Results: Cytotoxicity assay using Vero cells revealed CC50 = 409.71 ± 47.70 μg/ml for the extract whereas chebulagic
acid and chebulinic acid showed more than 95% cell viability up to 200 μg/ml. The extract from T. chebula
(IC50 = 0.01 ± 0.0002 μg/ml), chebulagic (IC50 = 1.41 ± 0.51 μg/ml) and chebulinic acids (IC50 = 0.06 ± 0.002 μg/ml)
showed dose dependent potent in vitro direct anti-viral activity against HSV-2. These also effectively prevented the
attachment as well as penetration of the HSV-2 to Vero cells. In comparison, acyclovir showed poor direct anti-viral
activity and failed to significantly (p > 0.05) prevent the attachment as well as penetration of HSV-2 to Vero cells when
tested upto 50 μg/ml. However, in post-infection plaque reduction assay, T. chebula extract, chebulagic and chebulinic
acids showed IC50 values of 50.06 ± 6.12, 31.84 ± 2.64, and 8.69 ± 2.09 μg/ml, respectively, which were much lower than
acyclovir (71.80 ± 19.95 ng/ml).
Conclusions: The results presented herein suggest that T. chebula extract, chebulagic and chebulinic acids have
higher direct antiviral activity against HSV-2 and efficacy to inhibit virus attachment and penetration to the host
cells as compared to acyclovir. However, acyclovir is more potent to inhibit post-infection virus replication. Hence,
T. chebula may be a useful candidate for developing alternative therapy for prevention of sexually transmitted
HSV-2 infection.
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Background
Herpes simplex virus-2 (HSV-2) is a double stranded
DNA virus belonging to the family Herpesviridae. It
causes genital herpes, contributing to the risk of HIV in-
fection through sexual route [1, 2]. HSV-2 is sexually
transmitted virus and infect 500 million people worldwide
and 20–23 million new infections are reported annually
[3], http://www.who.int/mediacentre/factsheets/fs400/en/
#hsv2. Since virus is an intracellular parasite in neural
ganglia, it is difficult to completely eliminate it [1, 4]. Nu-
cleoside derivatives such as acyclovir, valaciclovir, famci-
clovir and cidafovir have been widely used for the
treatment of HSV infection [5]. In addition to high cost,
treatment with acyclovir and other related drugs is also as-
sociated with the emergence of drug resistant strains [6],
which is a major hurdle in the immunocompromised indi-
viduals, co-infected with other opportunistic Sexually
Transmitted Infections (STIs) such as HIV-1 [7, 8].
Natural products from medicinal plants have been an
important source of new biologically effective compounds
exhibiting different modes of action against viral infection
[9–11]. Terminalia chebula Retz. (T. chebula) is an ever-
green flowering tree of the Combretaceae family and ex-
tensively used in traditional medicine. Pharmacological
studies revealed the inhibitory activity of T. chebula on
viral infections, such as human immunodeficiency virus
type 1 (HIV-1), herpes simplex virus-1 (HSV-1), cyto-
megalovirus (CMV) and influenza [12–16]. In addition,
the extract from T. chebula also has anti-bacterial, anti-
fungal, anti-carcinogenic, anti-oxidant, anti-diabetic and
anti-aging activities [17]. T. chebula has various phytocon-
stituents like tannins, flavonoids, sterols, amino acids,
fructose, resins and fixed oil etc. However, tannins such as
chebulinic acid, chebulagic acid, gallic acid, chebulic acid,
corilagin and ellagic acid may constitute 30% of various
phytochemicals [18, 19]. Though there are several studies
on the anti-HSV-1 activity of T. chebula extract and its
constituents namely chebulagic acid [15, 20, 21], but their
activity against HSV-2 needs to be addressed.
Keeping in view of the above, the 50% ethanolic extract
prepared from the fruits of T. chebula was evaluated for
direct anti-viral activity and its impact on the attachment
and penetration of the HSV-2 to the Vero cells. Chebula-
gic and chebulinic acids from T. chebula were also tested
in these assays and their activity compared with well
known drug, acyclovir. Additionally, the extract and pure
compounds were also evaluated for in vitro anti-HSV-2
activity in post-infection plaque reduction assay.
Methods
Plant material, preparation of 50% ethanolic extract, and
compounds
The fruits of Terminalia chebula were collected from the
medicinal plants garden of Ayurveda Research Institute,
Poojappura, Kerala and the identity was confirmed at Ayur-
veda Research Institute, Trivandrum, Kerala. The voucher
specimen (HLL/04/2013) has been kept at Natural Prod-
ucts Division of HLL Lifecare Limited, Trivandrum, Kerala,
India. Air and shade dried fruits were grinded and strained
through a 30 mesh (0.5 mm). The finely grinded powder
(24 g) was subjected to pressurized sequential extraction
using Accelerated Solvent Extractor (ASE 150, Dionex Inc.,
Sunnyvale, CA, USA) essentially as described previously
[22, 23]. In brief, the material was mixed with diatomaceous
earth at 4:1 ratio. The mixture was placed into a sample cell
(100 ml) and loaded onto the ASE 150 system. Extraction
was performed using 50% ethanol under pressure
(1500 psi) at 60 °C with a flush volume of 60% using 2 static
cycles. The solvent was then evaporated in a rotary evapor-
ator (Büchi Labortechnik AG, 9230 Flawil, Switzerland).
The dried extract was weighed and used for further studies.
Highly pure commercial chebulagic acid and chebuli-
nic acid, both purified from T. chebula, were obtained
from MP Biomedicals, Ohio, Solon, USA. These com-
pounds were used as reference standard to identify the
corresponding peaks in 50% ethanolic extract prepared
from fruits of T. chebula as well as to determine their
anti-HSV-2 activity in various assays as described below.
Both the compounds were dissolved in absolute ethanol
(10 mg/ml) and further dilutions were made in the culture
medium before use. Acyclovir (commercial name acyclo-
guanosin) was purchased from Sigma-Aldrich Inc., St.
Louis, MO, USA. It was dissolved in dimethyl sulphoxide
(DMSO) to make stock solution of 7 mg/ml and further
diluted in culture medium to prepare working concentra-
tion (s) prior to use. The final concentration of DMSO
was < 0.1% in various assays where acyclovir was used.
High performance liquid chromatography analysis
The Reverse Phase High Performance Liquid Chroma-
tography (HPLC; LC Agilent, Agilent Technologies,
Boblingen, Germany) of the plant extract was performed
using a Reverse phase XTerra RP 18 column (4.6 ×
250 mm, 5 μm; Waters Corporation, Milford, USA) and
pure compounds (chebulagic and chebulinic acids) were
used as reference standards. HPLC grade solvents were
purchased from Merck, Mumbai, India. The solvent sys-
tem used was 0.01% orthophosphoric acid in water :
acetonitrile (80 : 20) with a flow rate of 1 ml/min. The
peaks were detected at 272 nm. The extract was pre-
pared at a concentration of 5 mg/ml and the standards
at 1 mg/ml in the mobile phase solvent system and 20 μl
of each was injected for analysis. The data was processed
using open lab software (Agilent Technologies).
Cells and viruses
African green monkey kidney cells (Vero cells) were ob-
tained from National Centre of Cell Science, Pune, India
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and maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma-Aldrich Inc.) supplemented with 10%
fetal bovine serum (FBS; Biological Industries, Kibbutz
beit HaemeK, Israel) and an antibiotic-antimycotic cock-
tail [Penicillin (100 units/ml), Streptomycin (100 μg/ml)
and Amphotericin B (250 ng/ml); Pen-Strep-Ampho sol,
Biological Industries]. For HSV-2 G strain (VR-734;
ATCC, Rockville, USA) production, the Vero cell culture
was maintained at 37 °C in a humidified atmosphere of
5% CO2. The HSV-2 strain was propagated in the 25-
cm2 tissue culture flask for 72 h at 37 °C in CO2 incuba-
tor at multiplicity of infection (MOI) of 0.01 PFU/cell
[24]. After three cycles of freezing/thawing, the super-
natant was titrated on the basis of Plaque Forming Unit
(PFU) as previously described [24] and stored in aliquots
at −80 °C until use.
Cytotoxicity assay
The cytotoxicity of the 50% ethanolic T. chebula extract,
chebulagic acid, chebulinic acid and acyclovir was
assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide; Sigma-Aldrich Inc.] assay
[25]. In brief, Vero cells (1.25 × 104/well) were seeded in
96-well cell culture plates (Greiner Bio-One, GmbH,
Frickenhausen, Germany) and grown overnight at 37 °C
in humidified atmosphere of 5% CO2. After 24 h, cells
were treated with varying concentrations of the T. che-
bula extract, chebulagic acid, chebulinic acid and acyclo-
vir in duplicate along with vehicle [dimethyl sulfoxide
(DMSO) and/or ethanol] control for 48 h. Negative con-
trol included cells with medium only. After incubation,
20 μl of MTT (5 mg/ml in 50 mM PBS) was added per
well and incubated for 4 h at 37 °C, followed by addition
of MTT solvent (100 μl/well; 0.04 N HCl in absolute iso-
propanol). The absorbance (OD) was read at 540 nm
with reference filter at 630 nm by using microplate spec-
trophotometer (ELX 800MS; BioTek Instrument Inc.,
Vermont, USA). Percent viability was calculated by div-
iding the OD obtained in treatment group by OD in the
respective vehicle control multiplied by 100.
Anti-HSV-2 activity of the extract of T. chebula, chebulagic
acid and chebulinic acid
Direct anti-viral activity assay
To evaluate direct inactivation of HSV-2 by 50% ethano-
lic T. chebula extract, chebulagic acid and chebulinic
acid, HSV-2 virus (100 PFU) was pre-incubated with
sub-toxic serial concentrations of the T. chebula extract,
chebulagic acid, chebulinic acid and acyclovir at 37 °C
for 1 h. Subsequently, the contents were added to the
confluent Vero cells monolayer growing in a 24-well cell
culture plate (Corning Incorporated Costar, NY, USA)
followed by incubation at 37 °C for 1 h under the hu-
midified 5% CO2 atmosphere. After virus adsorption, the
supernatant was aspirated and infected cells were
washed twice with serum free DMEM and overlaid with
1% low melting point (LMP) agarose overlay medium.
After 48 h incubation, cells were fixed with 10% formal-
dehyde (in 50 mM PBS), stained with 0.2% crystal violet
and number of plaques counted. The percent plaque re-
duction was calculated as 100 – [(PT/PC) × 100], where
PT and PC refer to the number of plaques in the pres-
ence and absence of the compound, respectively. The
direct anti-viral activity was measured by plaque reduc-
tion as compared to the vehicle treated virus control.
The minimal concentration of the compound required
to inhibit 50% of plaque numbers (IC50) was calculated
by regression analysis of the dose–response curves of
the extract/compounds.
HSV-2 attachment and penetration assay
The attachment and penetration assays were performed
essentially as described previously [26, 27] with slight
modifications. In brief, for attachment assay, confluent
Vero cells grown in 24-well cell culture plates were pre-
chilled at 4 °C for 1 h. The medium was aspirated and
virus (100 PFU/well) was added in the presence or ab-
sence of the varying concentrations of 50% ethanolic T.
chebula extract, chebulagic acid, chebulinic acid and
acyclovir to the Vero cells and incubated for 3 h at 4 °C.
Subsequently, cells were washed twice with plain DMEM
medium, and processed as described in direct anti-viral
activity assay to determine IC50. In the penetration assay,
HSV-2 virus (100 PFU/well) was added to the pre-chilled
confluent monolayer of Vero cells growing in 24-well
culture plate for 3 h at 4 °C to allow attachment. The
medium was replaced with pre-warmed fresh medium
containing varying concentrations of test extract/com-
pounds and incubated at 37 °C to maximize virus penetra-
tion. After 30 min, the infected monolayer cultures were
treated with warm PBS (pH 3.0) for 1 min to inactivate
the non-penetrated viruses. After washing three times
with serum-free medium, cells were overlaid with 1%
LMP agarose and processed to quantitate the number of
plaques after 48 h incubation as described above.
Post-infection virus plaque reduction assay
The anti-HSV-2 activity of 50% ethanolic T. chebula ex-
tract, chebulagic acid, chebulinic acid and acyclovir has
been evaluated by using post-infection plaque reduction
assay [28]. In brief, Vero cells (8 × 104/well) were seeded
in 24-well cell culture plate and incubated at 37 °C in a
humidified atmosphere of 5% CO2 to form complete
monolayer. After incubation, medium was removed and
cells were infected with HSV-2 virus (100 PFU/well) for
1 h at 37 °C under humidified atmosphere of 5% CO2.
After virus adsorption, viral inocula was subsequently
removed by washing the cells twice with fresh serum
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free DMEM and cells were overlaid with 1% LMP agar-
ose, containing varying concentrations (less than calcu-
lated CC50 values) of the 50% ethanolic extract from T.
chebula, chebulagic acid and chebulinic acid. Acyclovir
was used as positive control and agar overlay containing
appropriate solvents (DMSO/ethanol), used to prepare
test compounds comprises the vehicle control. After
48 h incubation, plates were processed and number of
plaques counted.
Statistical analysis
The values are expressed as mean ± standard error mean
of three/four independent experiments performed in du-
plicate. For determination of the CC50 and IC50 values,
nonlinear regression of concentration-response curves
were prepared using GraphPad Prism 4 (GraphPad Soft-
ware Inc., CA, USA). The statistical significance in re-
duction of plaques in presence of T. chebula extract,
chebulagic acid, chebulinic acid and acyclovir versus re-
spective vehicle treated virus control was determined by
one-way ANOVA and p < 0.05 was considered statistically
significant. Significance among various treatment groups
was further analysed by using Tukey post-hoc test.
Results
T. chebula extract, chebulagic acid and chebulinic acid
showed potent direct anti-viral activity
The 50% ethanolic extract from the fruits of T. chebula
was prepared as described in Methods. From 24 g pow-
der, the average yield of 50% ethanolic extract was 15 g
(62.5% yield). Analysis of T. chebula extract by reverse
phase HPLC revealed multiple peaks, furthermore che-
bulagic acid and chebulinic acid revealed a retention
time of 11.2 and 29.2 min, respectively (Fig. 1). In
addition to these two major peaks, peak with retention
time of 3.4 min corresponded to gallic acid (Fig. 1).
Before evaluating the anti-HSV-2 activity of the 50%
ethanolic extract prepared from the fruits of T. chebula
or compounds chebulagic acid and chebulinic acid, their
effect on the viability of Vero cells was determined by
MTT assay as described in Methods. The extract of T.
chebula revealed 409.71 ± 47.70 μg/ml CC50 value
(Table 1). The chebulagic and chebulinic acids showed >
95% cell viability when tested up to 200 μg/ml. The
CC50 value of 351.85 ± 48.80 μg/ml was observed with
acyclovir (Table 1).
Anti-HSV-2 activity by direct inactivation of the virus
was tested in the presence of crude extract/compounds.
HSV-2 virus was pre-treated with varying concentrations
of T. chebula extract, chebulagic acid, chebulinic acid
and acyclovir followed by analysis of their ability to in-
fect Vero cells by formation of plaques as described in
Methods. The pre-treatment of HSV-2 with the plant ex-
tract, chebulagic acid as well as chebulinic acid showed a
significant reduction in the formation of plaques as
compared to vehicle treated virus control group with
IC50 values of 0.01 ± 0.0002, 1.41 ± 0.51, and 0.06 ±
0.002 μg/ml respectively (Table 1). The differential
anti-HSV-2 activity of the above treatment groups
with respect to each other was not significant using
one way ANOVA. The direct antiviral activity of the
T. chebula extract, chebulagic acid and chebulinic
acid was approximately 20 to 2900 fold higher than
acyclovir (IC50 = 29.04 ± 1.04 μg/ml; Table 1).
T. chebula extract, chebulagic acid and chebulinic acid
effectively inhibited HSV-2 attachment and penetration
to the Vero cells
Further, the effect of T. chebula extract, chebulagic acid,
chebulinic acid and acyclovir was also evaluated on the
attachment and penetration of HSV-2 to the Vero cells
as described in Methods. T. chebula extract, chebulagic
acid and chebulinic acid significantly inhibited in vitro
binding of HSV-2 to Vero cells in a dose-dependent
manner with the IC50 values of 0.48 ± 0.20, 1.66 ± 0.30,
and 0.29 ± 0.01 μg/ml as compared to vehicle treated
virus control respectively (Fig. 2). The differences among
the treatment groups of plant extract, chebulagic acid
and chebulinic acid for inhibition of HSV-2 attachment
to Vero cells was significant by one way ANOVA ana-
lysis. Furthermore, analysis by Tukey post-hoc test re-
vealed that anti-HSV-2 activity in the attachment assay
by chebulinic acid was significantly higher than chebula-
gic acid. Acyclovir, when tested up to a concentration of
50 μg/ml did not show any significant (p > 0.05) inhib-
ition in the HSV-2 binding to Vero cells as revealed by
the number of plaques observed as compared to DMSO
treated negative control (Fig. 2). Further, pre-treatment
of the Vero cells with the 10 μg/ml of T. chebula extract,
chebulagic acid & chebulinic acid and 1 μg/ml of acyclo-
vir followed by infection with HSV-2 did not show any
significant reduction in the number of viral plaques as
compared to vehicle treated cells, suggesting that the
above extract/compounds do not have any inhibitory ef-
fect on the host cell receptors (data not shown).
In addition to the attachment assay, we also observed
a concentration dependent significant inhibition of HSV-
2 penetration to the Vero cells by the T. chebula extract,
chebulagic acid and chebulinic acid with the IC50 values
of 0.99 ± 0.52 μg/ml, 4.65 ± 0.02 μg/ml, and 0.68 ±
0.05 μg/ml respectively with respect to vehicle treated
virus control (Fig. 3). The differences among the treatment
groups of plant extract, chebulagic acid and chebulinic
acid for inhibition of HSV-2 penetration in the Vero cells
was significant by one way ANOVA analysis. Further ana-
lysis of the data by Tukey post-hoc test revealed signifi-
cant differences between chebulagic acid treatment group
with respect to plant extract or chebulinic acid treatment
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Fig. 1 (See legend on next page.)
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groups. However, no significant difference was observed
between plant extract versus chebulinic acid treatment
group. As in attachment assay, chebulinic acid in the
penetration assay also showed highest anti-HSV-2 activity.
Acyclovir (50 μg/ml) did not reveal any significant
(p > 0.05) decrease in HSV-2 penetration to the Vero
cells under similar experimental conditions (Fig. 3).
T. chebula extract, chebulagic acid and chebulinic acid
showed reduced anti-HSV-2 activity as compared to
acyclovir in post-infection plaque reduction assay
In the post-infection plaque reduction assay, acyclovir
showed dose dependent significant inhibition of HSV-2
replication with an IC50 value of 71.80 ± 19.95 ng/ml
(Fig. 4). However, extract (IC50 = 50.06 ± 6.12 μg/ml) as
well as chebulagic (IC50 = 31.84 ± 2.64 μg/ml) and chebu-
linic (IC50 = 8.69 ± 2.09 μg/ml) acids showed approxi-
mately 120–700 fold lower IC50 values as compared to
acyclovir in the post-infection plaque reduction assay
(Fig. 4). Using Tukey post-hoc test, chebulinic acid
showed significantly higher anti-HSV-2 activity as com-
pared to plant extract as well as chebulagic acid. How-
ever, anti-HSV-2 activity was not significantly different
between plant extract versus chebulagic acid.
Discussion
In the present study, we have shown that the 50% etha-
nolic extract prepared from the fruits of T. chebula has
a very potent direct antiviral activity against HSV-2
(Table 1). The direct anti-viral activity of the aqueous
extract prepared from the seeds of T. chebula on influ-
enza A (H3N8) virus has also been reported [16].
Casuarinin, a hydrolyzable tannin isolated from the bark
of Terminalia arjuna Linn also showed potent virucidal
activity against HSV-2 at a concentration of 25 μM [29].
The observed direct anti-viral activity by the two hydro-
lyzable tannins namely chebulagic acid and chebulinic
acid purified from T. chebula against HSV-2 is reported
for the first time, which seems to be higher than casuari-
nin. The direct anti-viral activity of T. chebula extract,
chebulagic acid and chebulinic acid was also significantly
(p < 0.05) higher than acyclovir, a well known drug used
for the treatment of HSV infection. We speculate that
the direct anti-viral activity of T. chebula extract, chebu-
lagic acid and chebulinic acid may be due to their inter-
action with viral surface glycoproteins, causing alteration
in its function or by making virus particles inert and
prevent their attachment and spreading to the Vero cells.
Indeed hydrolyzable tannins such as chebulagic acid and
punicalagin have been shown to bind to glycoproteins of
various viruses thereby inhibiting their entry to the host
cells as well as prevent cell-to-cell spread (20, 21).
HSV requires its glycoproteins (gB, gC, gD, gH and gL)
to interact with the host cell receptors (heparan sulphate,
nectin-1 and nectin-2) followed by penetrating the mem-
brane by fusion process [30, 31]. T. chebula extract, che-
bulagic acid and chebulinic acid showed potent inhibition
of HSV-2 attachment (Fig. 2) as well as penetration (Fig. 3)
to Vero cells. It has been shown that casuarinin, inhibited
the attachment and penetration of HSV-2 to Vero cells
broadly through the disturbances of the viral glycoproteins
[29]. Chebulagic acid and punicalagin, the hydrolyzable
tannins isolated from the fruits of T. chebula, inhibited
HSV-1 viral particles and prevented their binding, pene-
tration and cell-to-cell spread, as well as secondary infec-
tion [20]. However, pre-treatment of the host cells with
chebulagic acid and punicalagin were not effective in
prevention of HSV-1 infection. Their inhibitory activities
targeted HSV-1 glycoproteins involved in the attachment
and membrane fusion, by blocking interaction with host
cell surface glycosaminoglycans. Antiviral activity of che-
bulagic acid and punicalagin was significantly reduced in
mutant cell lines deficient for heparan sulfate and chon-
droitin sulfate suggesting that these tannins may be inter-
fering in the interaction of HSV-1 glycoproteins with
heparan sulfate/chondroitin sulfate rather than lysis of
viral membrane [20]. It is likely that the T. chebula extract,
chebulagic acid and chebulinic acid also target HSV-2
Table 1 Cytotoxicity and direct antiviral activity against HSV-2
of the 50% ethanolic extract prepared from fruits of T. chebula,
chebulagic acid, chebulinic acids and acyclovir in Vero cells
Test compounds aCC50 (μg/ml) bIC50 (μg/ml)
T. chebula 50% ethanolic extract 409.71 ± 47.70 0.01 ± 0.0002
Chebulagic acid >200c 1.41 ± 0.51
Chebulinic acid >200c 0.06 ± 0.002
Acyclovir 351.85 ± 48.80 29.04 ± 1.04
Values in this table represent the mean ± SE of four independent experiments
performed in duplicate
aCC50 was the concentration that showed viability of 50% of the Vero cells
bIC50 was the concentration that inhibited 50% of HSV-2 activity in direct
anti- viral activity assay using Vero cells as host
c > 95% cells were viable at 200 μg/ml
(See figure on previous page.)
Fig. 1 HPLC profiles of 50% ethanolic extract prepared from the fruits of T. chebula, chebulagic acid and chebulinic acid. The crude extract prepared
from the fruits of T. chebula (100 μg), chebulagic acid (20 μg) and chebulinic acid (20 μg) were resolved by reverse phase HPLC using RP 18
column as described in Methods. The X-axis represents the time (min) and Y-axis represents the voltage (mAU) at 272 nm. Solvent used
was acetonitrile : H2O (20 : 80 v/v) supplemented with 0.01% orthophosphoric acid. a 50% ethanolic extract prepared from the fruits of T.
chebula, b chebulagic acid and (c) chebulinic acid. The peak corresponding to gallic acid in panel (a) was identified by running gallic acid
standard (data not shown)
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glycoproteins that are responsible for its binding to host
cell receptors. Failure of acyclovir to show any significant
decrease in the attachment as well as penetration of HSV-
2 to the host cells may be due to the fact that it primarily
works intra-cellularly by inhibiting virus replication.
The results shown in the present study revealed that
50% ethanolic extract prepared from the fruits of T. che-
bula, chebulagic acid and chebulinic acid also inhibited
post-fusion HSV-2 replication or spread to other cells,
which was approximately 120–700 fold lower as com-
pared to acyclovir. Keeping in view of the large molecu-
lar weight of chebulagic acid and chebulinic acid, it is
likely that they may not penetrate the Vero cells and
hence may not interfere in intracellular virus replication.
In contrast, acyclovir will enter the cells and inhibit
HSV-2 replication. Acyclovir is converted in the virus in-
fected cells to acyclovir monophosphate using viral-
encoded thymidine kinase and subsequently to acyclovir
triphosphate by using host cell enzymes, which prevent
virus DNA synthesis and thus replication by inhibiting
the viral DNA polymerase [32]. It is likely that T.
chebula extract, chebulagic acid and chebulinic acid
binds to viral glycoproteins expressed on the infected
Vero cell surface thereby rendering their unavailability
for cell-to-cell spread. However, further studies will be
required to understand the plausible mechanism by
which T. chebula extract, chebulagic acid and chebulinic
acid exhibit anti-HSV-2 activity in the post-infection
plaque reduction assay.
T. chebula fruit is one of the important ingredients of
Triphala-an important herbal preparation used for cen-
turies in the traditional Indian system of Ayurveda as
colon cleanser, digestive, diuretic and laxative [33]. The
extract prepared from the fruits of T. chebula or its con-
stituents have shown diverse pharmacological activities
which include, antioxidant and free radical scavenging
activity, anticarcinogenic activity, hepatoprotective activity,
cardioprotective activity, cytoprotective activity, antidiabetic
activity, antibacterial, fungal and viral activity, gasterointest-
inal motility improving and anti-ulcerogenic activity etc.
[17, 34–38]. Keeping in view of its acetylcholinestrase in-
hibitors activity, antioxidant and anti-inflammatory effects,
a b
c d
Fig. 2 Efficacy of the T. chebula extract, chebulagic acid, chebulinic acid and acyclovir to inhibit attachment of HSV-2 to Vero cells. HSV-2 (100 PFU) virus
along with various concentrations of the T. chebula extract, chebulagic acid, chebulinic acid and acyclovir was incubated for 3 h with the pre-chilled Vero
cells seeded in 24-well plates at 4 °C and processed for inhibition in the attachment of the virus as described in Methods. The Y-axis represents percent
inhibition in the number of plaques with respect to the vehicle treated virus control group. Values are expressed as mean ± SEM of the three
independent experiments performed in duplicate. Various panels are (a) extract of T. chebula, b chebulagic acid, c chebulinic acid and (d) acyclovir.
*p≤ 0.05, **p≤ 0.01, and ***p≤ 0.001 between treated and vehicle control at respective concentration of the extract/compound
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its potential for the treatment of alzheimer’s disease is also
being explored [39]. Interestingly, in vivo anti-viral property
of chebulagic acid, was also demonstrated by treating mice
challenged with a lethal dose of human enterovirus 71
(major causative agent of hand, foot and mouth disease in
younger children), which led to reduce mortality and clin-
ical symptoms mediated by inhibiting viral replication [40].
In another study, the extract prepared from T. chebula Retz
when administered along with acyclovir significantly cur-
tailed the development of skin lesion and prolonged the
mean survival rate of HSV-1 infected mice as compared to
when administered either acyclovir or herbal extract alone
[15]. These studies suggest the enormous clinical potential
of T. chebula for a variety of ailments. The obvious
question comes to mind about the safety of the T. che-
bula-based herbal preparations. The ethanolic extract
of T. chebula fruits did not show any mutagenic
properties as tested in bacterial mutation assays and
also did not reveal any toxic effects when repeatedly
administered orally in rats [41]. The anti-mutagenic
activity of the hydrolyzable tannins purified from T.
chebula has also been shown by another independent
study [42]. The fruits from T. chebula could reduce
the lead and almunium induced genotoxicity [38]. These
studies suggest that T. chebula extract and hydrolyzable
tannins are safe molecules to be used as therapeutic
agents against HSV. In contrast, a known side effect of
prolonged treatment with acyclovir is nephrotoxicity [43].
However, the extract of T. chebula has nephroprotective
activity [44]. Use of T. chebula extract, chebulagic and
chebulinic acids could improve the prognosis of sexually
transmitted HSV-2 as well as reduction of sexually trans-
mitted HIV-1 as co-infection. The extract of T. chebula
will also be useful against viruses that use glycosaminogly-
cans as entry door in to the host such as Hepatitis C, HIV
and dengue viruses. However, extensive investigations




Fig. 3 Efficacy of the T. chebula extract, chebulagic acid, chebulinic acid and acyclovir to inhibit penetration of HSV-2 to Vero cells. Pre-chilled
confluent monolayer of Vero cells growing in 24-well culture plate were incubated with HSV-2 (100 PFU) for 3 h at 4 °C followed by incubation with
the varying concentrations of the extract of T. chebula (a), chebulagic acid (b), chebulinic acid (c) and acyclovir (d) at 37 °C for 30 min to allow virus
penetration followed by assessment of plaque formation as described in Methods. Values are expressed as percent inhibition in the number of plaques
as compared to vehicle treated virus control. Each bar represents the mean ± SEM of three independent experiments performed in duplicate. *p≤ 0.05,
**p≤ 0.01, and ***p≤ 0.001 between treated and vehicle control at respective concentration of the extract/compound
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Conclusions
To the best of our knowledge, we have demonstrated for
the first time, anti-HSV-2 activity of T. chebula. Due to
potent direct antiviral activity against HSV-2 including
its attachment as well as penetration by T. chebula extract,
chebulagic acid and chebulinic acid, which is higher than
acyclovir, this plant may be a good source to identify
natural product (s). However, additional studies will be re-
quired to determine the mechanism by which T. chebula
and its constituents exhibit anti-HSV-2 activity.
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